Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – ...

According to TipRanks.com, Archila is a 5-star analyst with an average return of 11.4% and a 52.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis ...

Goldman Sachs analyst Asad Haider maintained a Hold rating on Pfizer yesterday and set a price target of $27.00. The company’s shares closed yesterday at $23.93. Take advantage of TipRanks Premium at ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

According to DelveInsight's analysis, the growth of the FAP inhibitor market is expected to be primarily driven by the anticipated launch of ...